In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ?-catenin, a historically "undruggable" protein, in just two months. This ...
Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, ...